GREY:DGCRF - Post by User
Post by
ready2go1on Apr 21, 2010 12:33pm
397 Views
Post# 17015382
What trials? (you ask)
What trials? (you ask) | 1004202 | Validation of the PCA3 Molecular Urine Test for Predicting Repeat Prostate Biopsy Outcome in the Placebo Arm of the Dutasteride REDUCE Trial | MP64 | Prostate Cancer: Markers II | Poster | Leonard Marks |
| 1005167 | Prostate Cancer Antigen (PCA3)-Score is most useful for prediction of biopsy (Bx)-outcome in low (<4) and intermediate (4-10 ng/ml) PSA-Ranges: Analysis of 1251 European men | MP62 | Prostate Cancer: Markers I | Poster | Alexander Haese |
| 1000935 | Predicting prostate biopsy outcome in a screening setting. PSA, PCA3, a kallikrein panel, the Riskcalculator or a combination? ERSPC Rotterdam. | MP64 | Prostate Cancer: Markers II | Poster | Monique J. Roobol |
| 1005279 | Validation of PCA3- based nomograms for predicting positive biopsy for prostate cancer | MP64 | Prostate Cancer: Markers II | Poster | Marco Auprich |
| 1005223 | The diagnostic performance of the PCA3-Score in relation to the number of biopsy (Bx) sessions: Results of a multinational analysis of 1251 men | POD62 | Prostate Cancer: Detection and Screening V | Podium | Alexander Haese |
| 1005243 | Initial prostate biopsy: PCA3 outperforms established risk factors of prostate cancer and increases multivariate predictive accuracy | POD62 | Prostate Cancer: Detection and Screening V | Podium | Marco Auprich |
| 1004230 | PCA3 Predicts Prostate Biopsy Outcome in Men Receiving Dutasteride: Results from the Dutasteride REDUCE Trial | MP62 | Prostate Cancer: Markers I | Poster | Gerald Andriole |
I was close to adding 100,000 shares last week but held back due to the frustration of my wife and the thoughts of a close friend, who is also a share holder, who asked me, when is enough, enough?
Here we are today, below what I would have paid. At some point, I would think that I am going to be right.